Authors
Latest:
Atopic Dermatitis — Going Beyond the PillThere is a real opportunity for pharma to support the under-served population of atopic dermatitis patients, writes Mariel Metcalfe.
Latest:
Medical Affairs’ Search for MeaningThe need to look beyond the function’s traditional performance measures to the one that really matters-patient outcomes.
Latest:
Medical Affairs’ Search for MeaningThe need to look beyond the function’s traditional performance measures to the one that really matters-patient outcomes.
Latest:
Medical Affairs’ Search for MeaningThe need to look beyond the function’s traditional performance measures to the one that really matters-patient outcomes.
Latest:
ICH E2B (R3) EudraVigilanceImpact, challenges and the importance of ensuring readiness with ICH E2B (R3) EudraVigilance.
Latest:
Establishing End-to-End Control of Product Labelling: A Guide for the C-SuiteGraham Francis sets out 5 critical business drivers for building a global enterprise labelling strategy over the year ahead.
Latest:
How Copay Management by Payers Is EvolvingA look into the complex battle between pharmaceutical manufacturers and payers for balance between medication access and budget management.
Latest:
The AI Boom in Healthcare: How Manufacturers Can PrepareKellie Rademacher identifies some of the key questions to consider when choosing an AI partner.
Latest:
Deploying the Cloud in GxP EnvironmentsMeeting the stringent cloud compliance and regulatory requirements in pharma.
Latest:
Productivity Vs. Compliance: The Balancing Act of ECM in Life SciencesWhile digital transformation in life sciences starts with digitization for compliance, it should be seen as a key lever of competitive advantage and success, writes Jaleel Shujath.
Latest:
Patient KOLs: Their Guide to Entering Crowded MarketsHow “patient influencers” look beyond price to help the industry evaluate newly-launched brands.
Latest:
Patient Empowerment and the Future of Pharma AdvertisingWith digitalization enabling patient engagement with their own health experience more than ever before, two critical elements will steer pharma’s advertising path.
Latest:
Clinical Trials Don't Have to Cost Too Much or Take Too LongA discussion of the cost and time put into clinical trials.
Latest:
Clinical Trials Don't Have to Cost Too Much or Take Too LongA discussion of the cost and time put into clinical trials.
Latest:
Clinical Trials Don't Have to Cost Too Much or Take Too LongA discussion of the cost and time put into clinical trials.
Latest:
KOLs: An Endangered BuzzwordKOLs have traditionally exerted their influence through research and publication on drug safety and efficacy, but now share the stage with other important measures.
Latest:
The GDPR: A Journey to ComplianceAshley Slavic details how Veeva Systems prepared for the EU data protection regulation, and what others can learn from the experience
Latest:
How to Select the Right ConsultantA variety of consultant options are available to the pharma industry; this article is a 3-step guide to selecting the right consultant.
Latest:
How to Select the Right ConsultantA variety of consultant options are available to the pharma industry; this article is a 3-step guide to selecting the right consultant.
Latest:
Patient Advocacy: an Overlooked Strategy for Achieving Equitable Market Success?Ellen Coleman outlines the highlights of a recent webinar on ensuring that patient advocacy is a key element of a market access strategy.
Latest:
Japan: Balancing Cost and Innovation through PricingGlobal pharma companies and Japan can create a win-win situation through a new pricing mechanism, writes Nobuko Kobayashi.
Latest:
Improving Regulatory Resource Management through Systematic MeasurementAs submissions complexity intensifies, the key to better resource management is better measurement, writes Adrian Leibert.
Latest:
2021 Research: The Impact of New Clinical Trial Approaches Adopted During Pandemic***Live: Tuesday, October 26, 2021 at 11 EDT | 8am PDT | 5pm CEST | 4pm BST*** Oracle Health Sciences reveals new research conducted to understand the technology adaptations that were made to clinical trials during the pandemic, the effect of these adaptations, and the impact of these changes on the future of clinical trials.
Latest:
Engaging with Stakeholders In the Information AgeWith so much information readily available companies have lost a significant level of control over how and when details about their progress in drug development and planning related to approval, launch, and commercialization are disseminated.
Latest:
Engaging with Stakeholders In the Information AgeWith so much information readily available companies have lost a significant level of control over how and when details about their progress in drug development and planning related to approval, launch, and commercialization are disseminated.
Latest:
Cloud Levels Playing Field for Emerging Life Sciences CompaniesA discussion of the benefits that a cloud-based strategy has to offer.
